Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

This study tests whether adding the hormone-blocking drug rezvilutamide to standard salvage radiation therapy and androgen deprivation therapy (ADT) improves outcomes for men with prostate cancer that has returned after surgery, based on a rising PSA level. **You may be eligible if...** - You are male, aged 40 or older - Your prostate cancer returned after surgery (shown by a rising PSA above 0.2 ng/mL on two consecutive tests at least 2 weeks apart) - Imaging scans (bone scan and CT/MRI) do not show visible local or distant spread - Your PSA dropped below 0.1 ng/mL for at least 6 months after surgery - You have one or more high-risk features such as a high post-surgery risk score, high Gleason grade (8–10), PSA peak above 0.5 ng/mL, or advanced tumor stage (pT3/T4) **You may NOT be eligible if...** - There is visible evidence of cancer spread on standard imaging - Your PSA did not drop appropriately after surgery - You have serious heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.